CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

Author's Avatar
Oct 01, 2018
Article's Main Image

- Trial to continue to full enrollment of all three treatment arms -

- Full data set expected to support determination of an optimal dose for planned Phase 3 development in patients with severe thrombocytopenia -

- Independent Data Monitoring Committee did not identify significant safety concerns -

PR Newswire